SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : DNAP unlocking DNA coding

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Olav who wrote (82)1/21/2003 2:55:39 PM
From: Olav  Read Replies (1) of 95
 
Law Enforcement Independently Validate DNAPrint's Forensics Tests
SARASOTA, Fla., Jan. 21 /PRNewswire/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) (the "Company"), the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that two of its forensics tests have successfully passed second-party blind validations. The results constitute an important step towards gaining acceptance for the new technology in the forensics community.

Two major forensic science organizations and one major metropolitan police department, that will remain unidentified, have independently validated the performance of Ancestry 2.0, the world's first genetic test for determining individual ancestry admixture proportions. Each submitted DNA samples of concealed identity and DNAPrint returned the results for evaluation. For each sample, the majority ancestry determined matched the self-reported race and when detected, the admixture was consistent with what was known from the family history. Another major molecular forensics company has independently and similarly validated DNAPrint's RETINOME test, which is the world's first test for the determination of iris color from DNA. DNAPrint expects to publish details on both methods in the near future.

"Our results to date from over 1,800 blind trials have shown that biogeographical ancestry knows few geopolitical or cultural boundaries and that through admixture, we are more connected to one another than had previously been believed," said Dr. Tony Frudakis, Ph.D., CEO of DNAPrint genomics. "The results obtained to date support our vision that the accurate measurement of individual ancestry admixture proportions and elements of population structure correlated with human pigmentation will ultimately contribute towards the construction of physical profiles from crime scene DNA."

About Ancestry 2.0

AncestrybyDNA is a revolutionary genetics test for determining ancestral admixture analysis within individuals. Specifically, the test measures the proportionality of IndoEuropean, sub-Saharan African, East Asian-Pacific Islander and Native American ancestry, and in so doing provides an estimate of identity or affiliation with each of the world's major continental populations. Ancestry 2.0 is the forensics brand of AncestrybyDNA. DNAPrint's Ancestry technology was originally developed as the cornerstone of the Companies ADMIXMAP platform for using admixture to map complex, common disease and drug response genes. In addition to the forensics labs discussed in this press release, the test has been independently validated by US News and World Report, Popular Science Magazine, Miami's WPLG Channel 10, Tampa's FOX Channel 13 news, Germany's ZDF news Channel, Discovery Europe, and the Australian Broadcasting Corporation. The test has been featured in articles by the New York Times, World Business Reports Financial Times, UPI and the Sarasota-Bradenton Herald and will be the focus of an upcoming edition of CBS Eye on America with Wyatt Andrews. For more information about the test, please visit www.ancestrybydna.com.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemopredictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

Media and Press Contacts:
Carrie Castillo
DNAPrint genomics, Inc.
Director, Corporate Communications
(941) 366-3400
castillo@dnaprint.com

SOURCE DNAPrint genomics, Inc.

CONTACT: Carrie Castillo, Director, Corporate Communications, of
DNAPrint genomics, Inc., +1-941-366-3400, or castillo@dnaprint.com/

Web site: dnaprint.com

ancestrybydna.com

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext